Dyslipidemia is a prominent risk factor for atherosclerotic cardiovascular disease (CVD) and impacts over half of US adults. Lifestyle interventions, particularly those incorporating medical nutrition therapy, are essential in the management of dyslipidemia, to halt progression towards advanced CVD and metabolic disease.
The primary objective of this multi-site, prospective case series was to measure changes in the plasma atherogenic lipid profile and metabolic syndrome-related variables in 24 overweight patients with dyslipidemia at baseline, 4 weeks after daily consumption of a proprietary, targeted nutrition formula providing macronutrient and micronutrient support. Key active ingredients included plant phytosterols, prebiotic isomalto-oligosaccharides (IMO), xanthohumol from Humulus lupulus L., antioxidant vitamins C and E, and pea or rice protein with added amino acids. Changes in variables were also evaluated in a subgroup of participants at 8 weeks.
At the end of 4 and 8 weeks, significant and positive changes were seen in several outcome variables, including the atherogenic lipid profile and cardiometabolic risk factors.
